Ondřej Čermák

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Jan van den Berg, H. Heidbuchel, S. Connolly, 2022, Lancet.

Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.

E. Antman, R. Giugliano, E. Braunwald, 2015, European heart journal.